Evaluation of cellular and humeral immune response of sheep vaccinated with inactivated Rift Valley Fever vaccine adjuvanted with Montanide Gel

Document Type : Original Article

Authors

1 Faculty of Veterinary Medecine, Mansoura University, Egypt.

2 Veterinary serum and vaccine research institute, Cairo, Egypt.

3 Faculty of Veterinary Medicine, Cairo University, Egypt

Abstract

Abstract: Rift Valley Fever (RVF) is an acute infectious zoonotic arthopod - born viral disease, affecting many species of animals and it causes great economic losses in animal wealth and transmited to human and has zoonotic implication. Vaccination of susceptible animals with RVF vaccines are the important factor for controlling the disease. This study was applied to improve the ordinary vaccine by using Montanide gel 01as adjuvant with comparing the results with the Aluminiumhydroxyde inactivated RVF vaccine, through evaluating the humeral and cellular immune response and duration of immunity in sheep vaccinanted with the prepared vaccines. the antibody titre in the group vaccinated with montanide gel inactivated RVF vaccine reached the protective level at the 7th day post vaccinatin and stay within the proteceive level till the end of the 11th month in the group vaccinated with one dose of montanide gel inactivated RVF vaccine and till the end of 12th month in sheep vaccinated with the same vaccine. These results revealed that the best vaccine is 20% montanide gel inactivated RVF vaccine when used as two doses which gave higher level of antibody all over the period of the test compared with that of other vaccinated groups. Also the results of cell mediated immune response showed that: (i) The cell proliferation expressed by optical density showed early significance in sheep vaccinated by montanide gel inactivated RVF vaccine and slight elevation in sheep vaccinated by aluminium hydroxide gel inactivated RVF vaccine.

Keywords

Main Subjects

References

ABDEL-GAFFAR, S.; MOHSEN, A.; AYOUB, N.; EL-NIMR, M. AND FATHIA, M. 1979. Rift Valley fever in Egypt III. Diagnosis and vaccination.14th Arab. Vet. Cong., 24-29 march Cairo, page 1-11.
ABUL-MAGD D.M. 2014.Vaccination against Rift Valley Fever disease. PhD.Thesis, Department of Animal Medicine  Faculty of Veterinary Medicine, Benha University,.
ARONTHEY AND HAZEN  1988.  Role of yeast cell growth temperature on candida Albicans virulence in mice. Immunol, 56; 2884- 2890.
 BLACKBURN, N. K. AND BESSELAAR, T. G. 1991. A study of the effect of chemical inactivants on the epitopes of Rift Valley fever virus glycoproteins using monoclonal antibodies. J Virol Methods 33:367-374.
DALSGARRD, K.; HILGERS,L. AND TROUVE,G. 1990. Classical and new approache to adjuvant use in domestic animals. Adv. Vet. Sci.Comp. Med., 35: 121-159.
DEVILLE S, PARKER R. AND LAVAL A. 2008.  Adjuvant formulation for infeluenza H1N1 and H3N2 pig vaccines: MontanideTM Gel safety and Efficacy study.Proceedings of the Conference of Research of Workers in Animal Disease, Chicago.
DEVILLE S, CARNEAUX E, BERTRAND F, CAUCHARD S, CAUCHARD J AND DUPUSISL 2011. Adjuvant formulation for companion  animals vaccines. Procedia in Vaccinology (4):104-112.
DIGOUTTE J.P. AND PETERS C.J.1989. General aspects of the 1987 Rift Valley fever epidemic in Mauritania. Res. Virol.; 140:27– 30.
DUPUIS, L.; DEVILLE, S.;BETERAND, F. ; LAVAL, A. AND AUCOUTURIER, J. 2008. Adjuvant formulation for multivalent pig vaccines: Pasteurella multocida anatoxins and inactivated Bordetella bronchiseptica, Montanide Gel 01TM safety study. proceedings of the international pig veterinary society. Durban. Rift Valley Fever. Adv. Vet. Sci., 10(65): 127.
EBRAHIM, B., ROY, D.J., BIRD, P. AND SANGER, D.R. 1995. Cloning, sequencing and expression of the ovine Interlukin -6 gene. Cytokine, 7: 232-236.
EDUARD, K.1985. Progress in enzyme immunoassays : production of reagents, experimental design and interpretation . Bulletin of the world health organization, 63(4):793-811.
EMAN. M. S. S.1995. Studies on RVF vaccine inactivated with Binary. Ph. D. Sc. Thesis Microbiology, Fac. of Vet. Med., Cairo -Univ.
El NIMR, M.M.1980. Studies on the inactivated vaccine against  Rift Valley Fever. Ph. D. Thesis (Microbiology) Fac. Vet. Med. Assuit Univ. Egypt.
El SAYED ,E.L.;ABDEL-HADY, M.K.; ZAKI, E.S.A.; MAHMOUD, M.S.; AHMED, I.K.. AND GHALY, H.M.2011. Study on improvement of Entero-3 vaccine using montanideTM gel as an adjuvant. Proceeding of 4thScientfic Conference of Animal Wealth Research in middle East and north Africa, foreign agriculture relations (FAR), Egypt,551-559.
FAFETINE, J.M.; TIJHAAR, E.; PAWESKA, J.T.; NEVES, L.C.; HENDRIKS, J.; SWANEPOEL, R.; COETZER, J.A.; EGBERINK, H.F. AND RUTTEN, V.P. 2007. Cloning and expression of Rift Valley fever virus nucleocapsid (N) protein and evaluation of a N-protein based indirect ELISA for the detection of specific IgG and IgM antibodies in domestic ruminants Vet. Microbiol,; 121 (1-2): 29-38.
HAMMAD, M.Y. 2015.  Some studies on Rift Valley Fever vaccine, PhD. Thesis,  Faculty of veterinary medicine, Benha University.
HARMON, B G. AND GLISSON, J. R.1989.  In vitro microbial activity of avian peritoneal macrophages. Avian Dis., 33: 177-181.
HEBA ABD El-MONEM KHAFAGY 2013. Some studies on living attenuated Rift Valley Fever vaccine.M. Vet. Sic Thesis, (Infectious), Fac. Vet. Med. Benha. Univ.
 HUSSEIN, H.A.1989.  Immuno suppressive effect of MDV M.V.SC, Thesis, Department of Virology Fac. of Vet. Medicine, Cairo Univ. 
IRENE S. LEAL, BRGITTE SMEDEGARD, PETER ANDERSEN, AND RUI APPELBERG 1999. interleukin 6 and interleukin 12 participate in induction of type 1 protective t-cell response during vaccination with a tuberculosis subuinit vaccine. Infect immune; 67 (11): 5747-5754.
KATHRYN, A.; HUBBARD, B. S. C.; ARTHUR BUSKERVILLE, AND JOHN 1991. Ability of a mutagenized virus variant to protect young lambs from Rift Valley Fever. Am. J. Vet. Res., Vol.52: 50-5.
MACPHERSON, J.A. AND STOCKER,N.G. 1962. Polyoma Transformation of hamester cell clones an investigation of hamester cell clonesof genetic factors affecting all competence. Virology, 16: 147-151.
OIE, 1989. Manual of recommended diagnostic techniques and requirements for biological products of lists A and B diseases. Internation. Committee of the OIE, Vol. 2 P. 1/8 - 8/8.
OIE  2012.  OIE Terrestrial manual 2012, chapter 2.1.14.
OIE, 2014.  Rift Valley Fever, chapter 2.1.14.
LEE, L.F. 1984.  Proliferative response of chicken B and T lymphocyte to mitogene. Vet.Med, 15:44-52.
LUCY, F .L. 1977.  Chicken  Lymphocyte stimulation by mitogenes .Amicroassay with whole blood cultures. Avian Dis., 22:296-307.
MONA, F. M. 2008.  Experimental studies of Smithburn Attenuated Rift Valley Fever Virus Vaccine in pregnant sheep. Ph. D. Thesis (Virology).  Fac. Vet. Med. Benha University, Egypt.
PARKER, R.; DEVLLE, S.; DUPUIS, L.; BERTR, F. AND AUCOUTURIER, J. 2009. Adjuvant formulation for veterinary vaccines: Montanide Gel 01TM safety profile procedia in Vaccinology, 1(1) 140-147.
REED, L. J. AND MUENCH, H. 1938. A SIMPLE METHOD FOR ESTIMATING 50 PERCENT END POINT. AM, J. HYG., 27:493-497.
RICHARDSON AND SMITH, 1981. Resistance of virulent and attenuated strains of Candida albicans to intracellular killing by human and mouse phagocytes.J. Infect. Dis.; 144:557-565.
SANGEETA BUDHIA, LISA F. HARING, IAN MCCONNELL, And BARBARA A. BLACKAWS 2006. quantitation of ovine cytokine mRNA by real-time RT-PCR. Journal of immunological methods 309. 160-172.
SCUDIERO, D. A.; SHOEMAKER,R.H.; PAULL, K.D.;MONKS, A.;  TIERNEY, S.; NOFZIGER, T.H.; CURRENS, M. J.; SENIFF, D. AND BOYD, M. R.1988.  Evaluationa of soluble tetrazolium / Formazan Assay for cell growth and drug sensitivity in culture using human and other tumer cell lines. Cancer Res., 48:4827-4833.
SLATER, T.F., SAWYER, B. C. AND STRIIULI, U. 1963. Biochim. Biophys.Acta, 77, 383.
SPSS .2007. SPSS Inc. Released 2007. SPSS for Windows, Version 16.0. Chicago, SPSS Inc.
TAHA, M. M.; ELIAN, K.; GIHAN, K.; HASSAN, K. AND FATMA, S. 2002.  Standardization of both Rift Valley Fever cell lysate and supernatant antigens used in ELISA comparing with SNT& AGPT. Vet. Med. J., Giza. Vol. 50, No. 4. 987 – 992.
VOLLER, A.; BIDWELL, D. AND BARTLETT, A. 1976. Microplate enzyme immunoassay for the immunodiagnosis of virus infection .Am. Soc. for Micro., 506-512.
 WHO 1983.  The  use of vet. Vaccines for prevention and control of RVF. Bulletin of the World Health Org., 61(2): 261-8 .
Journal of Applied Veterinary Sciences
Volume 5, Issue 1
January 2020
Pages 22-34

Files

History

  • Receive Date: 01 January 2020
  • Accept Date: 01 February 2020

Share

How to cite

Statistics